Welcome to TV-44749 (Olanzapine) - a long-acting injectable being developed for the treatment of schizophrenia

Intended Audience

Eligible users are individuals from public and private sector payors (eg, third-party payors, health plan sponsors, state Medicaid programs), formulary committees (eg, Pharmacy and Therapeutics Committees), drug information centers, technology assessment committees, pharmacy benefit managers, third party administrators, and other multidisciplinary entities that, on behalf of healthcare organizations (eg, integrated delivery networks, hospitals, and health systems), review scientific and/or technology assessments to make drug or device selection or acquisition, formulary management, and/or coverage and reimbursement decisions on a population basis. Life sciences manufacturer representatives, including but not limited to pharmaceutical, biotechnology, and medical device industries, are not eligible to register for the healthcare decision-maker version of Tevamedical.com.

Important Notice

Information regarding pipeline products or investigational uses does not imply FDA approval and does not establish safety or efficacy. There is no guarantee that pipeline products or investigational uses will receive FDA approval. Teva does not recommend use of its medicines outside FDA-approved labeling.

Healthcare Economic Information

Healthcare economic information is provided pursuant to FD&C Act §502(a), as amended by FDAMA 114 and the 21st Century Cures Act.

Non-Dissemination Requirement

These materials are not intended for further distribution. Please do not download, disseminate, share, or forward the content to individuals outside the intended audience described above.

Attestation

By selecting “TV-44749 (Olanzapine) video” you acknowledge the information above and certify that you are a U.S. population health decision-maker, including healthcare institutions, payers, PBMs, formulary committee members.